UCB announced that the USFDA has approved Nayzilam (midazolam) nasal spray for the acute treatment of seizure clusters patients over 12 year-old with epilepsy. According to the news, this is the first and only FDA-approved group of seizures for nasal administration.

Epilepsy is a chronic neurological disease of the brain. It is the fourth largest neurological disease in the world, affecting approximately 65 million people. It is estimated that there are 150,000 epileptic seizures in the United States. Acute treatment of cluster seizures is critical because the risk of physical injury, nerve damage, and prolonged seizures will increase if untreated. However, existing methods of treatment for epilepsy are not suitable for treating cluster seizures, resulting in many patients not receiving treatment.

Nayzilam is a short-term treatment for cluster seizures. The patient can carry this disposable nasal spray. It can be used by non-medical professionals for patients who are having seizures. Its main component is benzodiazepine.

上一页: 全新给药方式，FDA批准癫痫新疗法上市

下一页: FDA批准诺华Piqray（Alpelisib），首个乳腺癌PI3K抑制剂